Shares of TELA Bio TELA decreased 2.3% after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 7.55% over the past year to ($0.57), which missed the estimate of ($0.52).
Revenue of $7,558,000 up by 115.51% year over year, which beat the estimate of $6,310,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
TELA Bio hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Aug 11, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/ax722gjq
Technicals
Company's 52-week high was at $18.00
Company's 52-week low was at $11.03
Price action over last quarter: Up 4.59%
Company Description
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
